Opinions of Czech general practitioners on generic drugs and substitution

• Authors: Martin Dosedel , Josef Maly , Ales Kubena , Jiri Vlcek
• Languages of publication: EN

Abstracts

EN

The aim of the study was to map and analyze general practitioners` opinions of, attitudes towards and experiences with generic drugs and generic substitution (GS) in the Czech Republic. General practitioners (GPs) who took part in the annual and regional professional conferences of the Society of General Practice in the period from November 2008 until March 2009 were asked to complete the 28-item questionnaire concerning the issue of generic drugs and GS. Questions were organized in 5 sections aimed at assessing the attitude towards GS, understanding the legislation and opinions on statements related to GS. All data were analyzed using descriptive statistics and correlations were tested by selected parametric and non-parametric tests. Total of 263 completed questionnaires were returned (mean age of 52.2 years (SD=13.7), 177 (67.3%) females and 248 (94.3%) GPs having a practice specialization). 99 (37.6%) respondents have considered generic drugs to be bioequivalent to the respective brand name drugs. 121 (46.0%) respondents believed that generic drugs are of lower quality than brand name drugs. None of respondent showed acquaintance with all the legal rules for GS. Awareness of the legislation and attitude towards GS correlated with the age (p<0.001). In conclusion, distrust among GPs in generic drugs derives from poor knowledge and personal experiences.

Keywords

EN

General practitioner; Brand name drug; Generic drug; Generic substitution

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2014
• Volume: 9
• Issue: 6
• Pages: 830-838

Dates

published

1 - 12 - 2014

online

16 - 8 - 2014

Contributors

author

Martin Dosedel

• Department of Social and Clinical Pharmacy, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, 500 05, Hradec Kralove, Czech Republic

author

Josef Maly

• Department of Social and Clinical Pharmacy, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, 500 05, Hradec Kralove, Czech Republic

author

Ales Kubena

• Department of Social and Clinical Pharmacy, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, 500 05, Hradec Kralove, Czech Republic

author

Jiri Vlcek

• Department of Social and Clinical Pharmacy, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, 500 05, Hradec Kralove, Czech Republic

References

• [1] Shrank W.H., Choudhry N.K., Liberman J.N., Brennan T.A., The use of generic drugs in prevention of chronic disease is far more cost-effective than thought, and may save money, Health Aff (Millwood)., 2011, 30, 1351–1357 http://dx.doi.org/10.1377/hlthaff.2010.0431[Crossref]
• [2] Pechlivanoglou P., van der Veen W.J., Bos J.H., Postma M.J., Analyzing generic and branded substitution patterns in the Netherlands using prescription data, BMC Health Serv Res., 2011, 11 [Crossref][WoS]
• [3] Institute of Health Information and Statistics of the Czech Republic. Economic information on health care 2010 [online]. 2011 [cited 2012-5-25]. Available from http://www.uzis.cz/en/publications/economic-information-health-care-2010
• [4] Aalto-Setälä V., The impact of generic substitution on price competition in Finland, Eur J Health Econ., 2008, 9, 185–191 http://dx.doi.org/10.1007/s10198-007-0059-0[Crossref][WoS]
• [5] Posner J., Griffin J.P., Generic substitution, Br J Clin Pharmacol., 2011, 72, 731–732 http://dx.doi.org/10.1111/j.1365-2125.2011.03920.x[Crossref][WoS]
• [6] Dylst P., Simoens S., Generic Medicine Pricing Policies in Europe: Current Status and Impact, Pharmaceuticals., 2010, 3, 471–81 http://dx.doi.org/10.3390/ph3030471[Crossref]
• [7] Czech Republic, Act No. 378/2007 on Pharmaceuticals, In: Catch III Registration of pharmaceuticals and steps related to their registration, Article 25, 2008, 115, 22–3, (in Czech)
• [8] State Institute for Drug Control, The physician’s and pharmacist’s roles derived from the new Act on Pharmaceuticals, Pharmacotherapeutic information 2/2008, A monthly for physicians and pharmacists, 2008, 2, 1–4, (in Czech)
• [9] Andersson K., Sonesson C., Petzold M., Carlsten A., Lönnroth K., What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden, Pharmacoepidemiol Drug Saf., 2005, 14, 341–348 References http://dx.doi.org/10.1002/pds.1055[Crossref]
• [10] Mott D.A., Cline R.R., Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution, Med Care., 2002, 40, 662–674 http://dx.doi.org/10.1097/00005650-200208000-00006[Crossref]
• [11] Suh D.C., Trends of generic substitution in community pharmacies, Pharm World Sci., 1999, 21, 260–265 http://dx.doi.org/10.1023/A:1008781619011[Crossref]
• [12] Shrank W.H., Stedman M., Ettner S.L., DeLapp D., Dirstine J., Brookhart M.A., et al., Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use, J Gen Intern Med., 2007, 22, 1298–1304 http://dx.doi.org/10.1007/s11606-007-0284-3[WoS][Crossref]
• [13] Andersson K., Jörgensen T., Carlsten A., Physicians’ opinions and experiences of the Pharmaceutical Benefits Reform, Scand J Public Health., 2006, 34, 654–659 http://dx.doi.org/10.1080/14034940600551111[Crossref]
• [14] Heikkilä R., Mäntyselkä P., Hartikainen-Herranen K., Ahonen R., Customers’ and physicians’ opinions of and experiences with generic substitution during the first year in Finland, Health Policy., 2007, 82, 366–374 http://dx.doi.org/10.1016/j.healthpol.2006.10.006[Crossref][WoS]
• [15] Lagarce L., Lusson-Brisset C., Bruhat C., Diquet B., Lainé-Cessac P., How practitioners view generic drugs: an opinion study from general practitioners in Maine-et-Loire (France), Therapie., 2005, 60, 67–74, (in French) http://dx.doi.org/10.2515/therapie:2005009[Crossref]
• [16] Himmel W., Simmenroth-Nayda A., Niebling W., Ledig T., Jansen R.D., Kochen M.M., et al., What do primary care patients think about generic drugs?, Int J Clin Pharmacol Ther., 2005, 43, 472–479 [Crossref]
• [17] Kersnik J., Peklar J., Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies, J Clin Pharm Ther., 2006, 31, 577–583 http://dx.doi.org/10.1111/j.1365-2710.2006.00776.x[Crossref]
• [18] García A.J., Martos F., Leiva F., Sánchez de la Cuesta F., Generic drugs: good or bad? Physician’s knowledge of generic drugs and prescribing habits, Gac Sanit., 2003, 17, 144–149, (in Spanish) http://dx.doi.org/10.1016/S0213-9111(03)71712-9[Crossref]
• [19] Hassali M.A., Stewart K., Kong D.C., A national survey on knowledge and perceptions of senior medical students in Australia about generic medicines, Med J Aust., 2008, 188, 123–124
• [20] Institute of Health Information and Statistics of the Czech Republic, Physicians, Dentists and Pharmacists 2008 [online]. 2010 [cited 2012-5-25]. Available from www.uzis.cz/system/files/lekfar2008.pdf
• [21] Banahan B.F., III, Kolassa E.M., A physician survey on generic drugs and substitution of critical dose medications, Arch Intern Med., 1997, 157, 2080–2088 http://dx.doi.org/10.1001/archinte.1997.00440390066010[Crossref]
• [22] European Medicines Agency, Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1/Corr ** [online]. 2010 [cited 2012-5-25]. Available from http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf
• [23] Davit B.M., Nwakama P.E., Buehler G.J., Conner D.P., Haidar S.H., Patel D.T., et al., Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration, Ann Pharmacother., 2009, 43, 1583–1597 http://dx.doi.org/10.1345/aph.1M141[WoS][Crossref]
• [24] Czech Republic, Act No. 48/1997 on public health insurance, In: Part VI Regulation of pricing and reimbursement of drugs and food for special medical purposes, Article 39, 1997, 16, 35–59, (in Czech)
• [25] Gomez Y., Adams E., Hoogmartens J., Analysis of purity in 19 drug product tablets containing clopidogrel: 18 copies versus the original brand, J Pharm Biomed Anal., 2004, 34, 341–348 http://dx.doi.org/10.1016/S0731-7085(03)00533-8[Crossref]
• [26] Reppe L.A., Stenberg-Nilsen H., Harg P., Hegge A.B., Lillefloth A.K., Buajordet I., Adverse events related to substitution of generic products in Norway 2005, Tidsskr Nor Laegeforen., 2008, 128, 2696–700, (in Norwegian)
• [27] Kopečná E., Deščíková V., Vlček J., Mladá J., Adverse drug reaction reporting in the Czech Republic 2005–2009, Int J Clin Pharm., 2011, 33, 683–689
• [28] Chandeclerc M.L., Tréchot P., Martin S., Weber-Muller F., Schmutz J.L., Barbaud A., Cutaneous adverse drug reaction induced by a generic substitute of Zyloric with a residual sensitization to allopurinol, Allergy., 2006, 61, 1492–1493 http://dx.doi.org/10.1111/j.1398-9995.2006.01199.x[Crossref]
• [29] Mumoli N., Cei M., Luschi R., Carmignani G., Camaiti A., Allergic reaction to Croscarmellose sodium used as excipient of a generic drug, QJM., 2011, 104, 709–710 http://dx.doi.org/10.1093/qjmed/hcq175[Crossref][WoS]
• [30] Kesselheim A.S., Stedman M.R., Bubrick E.J., Gagne J.J., Misono A.S., Lee J.L., et al., Seizure outcomes following the use of generic versus brand name antiepileptic drugs: a systematic review and meta-analysis, Drugs., 2010, 70, 605–621 http://dx.doi.org/10.2165/10898530-000000000-00000[WoS][Crossref]
• [31] Kesselheim A.S., Misono A.S., Lee J.L., Stedman M.R., Brookhart M.A., Choudhry N.K., Shrank W.H., Clinical equivalence of generic and brand name drugs used in cardiovascular disease: a systematic review and meta-analysis, JAMA., 2008, 300, 2514–2526 http://dx.doi.org/10.1001/jama.2008.758[Crossref][WoS]
• [32] van der Meersch A., Dechartres A., Ravaud P., Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review, PLoS One., 2011, 6
• [33] Timonen J., Bengtström M., Karttunen P., Ahonen R., The impact of generic substitution on the activities of pharmaceutical companies - a survey from the companies’ perspective one year and five years after the introduction of generic substitution in Finland, BMC Clin Pharmacol., 2010, 10 [Crossref]
• [34] Johnston A., Asmar R., Dahlöf B., Hill K., Jones D.A., Jordan J., et al., Generic and therapeutic substitution: a viewpoint on achieving best practice in Europe, Br J Clin Pharmacol., 2011, 72, 727–730 http://dx.doi.org/10.1111/j.1365-2125.2011.03987.x[WoS][Crossref]
• [35] Meredith P., Bioequivalence and other unresolved issues in generic drug substitution, Clin Ther., 2003, 25, 2875–2890 http://dx.doi.org/10.1016/S0149-2918(03)80340-5[Crossref]
• [36] Danish Health and Medicines Authority, Bioequivalence and labeling of medicines with regard to generic substitution [online]. Updated 2012-2 -07 [cited 2012-5-25]. Available from http://laegemiddelstyrelsen.dk/en/topics/authorisationand-supervision/licensing-of-medicines/marketingauthorisation/application-for-marketing-authorisation/bioequivalence-and-labelling-of-medicine-bstitution.aspx
• [37] Duerden M.G., Hughes D.A., Generic and therapeutic substitutions in the UK: are they a good thing?, Br J Clin Pharmacol., 2010, 70, 335–341 http://dx.doi.org/10.1111/j.1365-2125.2010.03718.x[WoS][Crossref]
• [38] Simoens S., Generic and therapeutic substitution: ethics meets health economics, Int J Clin Pharm. 2011, 33, 469–470 [Crossref][WoS]

Identifiers

DOI

10.2478/s11536-013-0344-5